HU
$2.01
-0.07
(-3.60%)
As of Oct 22, 2026, 5:48 PM EDT
Price history
Tuhura Biosciences Inc (HURA) is trading down at $2.01 (-3.60%), as of the latest quote. It operates in the Health Care sector.
Tuhura Biosciences Inc revenue & net income history (FY2015–FY2025)
RevenueNet income
| FY2015Jun 2015 | FY2016Jun 2016 | FY2017Jun 2017 | FY2018Jun 2018 | FY2019Jun 2019 | FY2020Jun 2020 | FY2021Jun 2021 | FY2022Jun 2022 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | — | — | — | — | — | — | — | — | $0 | $0 |
| Net income | −$4.35M | $8.86M | $8.08M | $11.1M | −$8.05M | −$9.13M | −$38.3M | −$22.7M | −$21.7M | −$30.1M |
| EPS (diluted) | $440.00 | — | — | — | — | — | — | — | −$1.21 | −$0.63 |
| Balance sheet | ||||||||||
| Cash and equivalents | $1.75M | $6.16M | $6.59M | $5.97M | $3.72M | $2.39M | $10.5M | $11.8M | $12.7M | $3.62M |
| Total assets | $2.58M | $6.36M | $7.91M | $7.07M | $4.04M | $2.94M | $13.5M | $15.9M | $20.0M | $27.4M |
| Total liabilities | $3.40M | $1.50M | $1.33M | $1.64M | $2.07M | $2.67M | $2.96M | $4.15M | $5.37M | $6.42M |
| Long-term debt | $1.02M | $693.7K | $28.1K | $1.12K | — | — | — | — | — | — |
| Shareholders' equity | −$821.5K | $4.86M | $6.58M | $5.44M | $1.97M | $263.0K | $10.6M | $11.8M | $14.6M | $20.9M |
| Cash flow | ||||||||||
| Operating cash flow | −$3.85M | −$5.15M | −$8.02M | −$9.85M | −$6.33M | −$7.93M | −$18.9M | −$20.4M | −$14.7M | −$27.6M |
| Capital expenditure | — | — | — | — | — | — | — | $180.0K | $57.9K | $76.1K |
| Free cash flow | — | — | — | — | — | — | — | −$20.6M | −$14.8M | −$27.7M |
RevenueNet income
| Q3 FY24†Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25†Jun 2025 | Q3 FY25†Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | — | $0 | $0 | $0 | — | $0 | — |
| Net income | −$5.58M | — | −$6.66M | −$9.52M | −$7.10M | — | −$7.54M | −$9.22M |
| EPS (diluted) | −$0.54 | — | −$0.15 | −$0.21 | −$0.14 | — | −$0.13 | −$0.14 |
| Balance sheet | ||||||||
| Cash and equivalents | $3.02M | $12.7M | $6.22M | $8.51M | $2.70M | $3.62M | $6.30M | $996.0K |
| Total assets | $4.14M | $20.0M | $14.6M | $34.6M | $25.7M | $27.4M | $29.7M | $31.7M |
| Total liabilities | $2.44M | $5.37M | $4.78M | $15.2M | $8.92M | $6.42M | $6.51M | $13.2M |
| Long-term debt | — | — | — | — | — | — | — | $3.60M |
| Shareholders' equity | −$2.77M | $14.6M | $9.86M | $19.4M | $16.8M | $20.9M | $23.2M | $18.5M |
| Cash flow | ||||||||
| Operating cash flow | −$1.89M | — | −$4.74M | −$6.25M | −$11.1M | — | −$4.41M | −$8.63M |
| Capital expenditure | $0 | — | $42.7K | $5.56K | $0 | — | $48.8K | $137.0K |
| Free cash flow | −$1.89M | — | −$4.78M | −$6.25M | −$11.1M | — | −$4.46M | −$8.77M |
From Tuhura Biosciences Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Tuhura Biosciences Inc
- Headquarters
- Tampa, Florida From SEC filings, Oct 2026
Recent News (1)
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International